{"filing":{"accession_number":"0001104659-26-111583","cik":"0001425205","ticker":"IOVA","company_name":"IOVANCE BIOTHERAPEUTICS, INC.","form":"8-K","filing_date":"2026-09-29","report_date":"2026-09-29","primary_document":"tm2626507d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1425205/000110465926111583/tm2626507d1_8k.htm"},"events":[{"id":35584,"run_id":32783,"accession_number":"0001104659-26-111583","anchor_item_number":"8.01","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"Iovance issued a press release on September 29, 2026 updating its full year 2026 revenue guidance from $350–$370 million to $410–$420 million, representing a $55 million increase at the midpoint (~15% upward revision). The disclosure includes financial metrics (record Q2 2026 revenue of $99.3 million, ~60% annual growth), operational updates (authorized treatment center expansion to ~100 centers), and forward-looking commentary on profitability. This is a material update to financial guidance that would affect a reasonable investor's assessment of the company's commercial performance and outlook.","company_name":"IOVANCE BIOTHERAPEUTICS, INC.","ticker":"IOVA","filing_date":"2026-09-29","form":"8-K","submitted_at":null,"items":[{"id":39683,"accession_number":"0001104659-26-111583","item_number":"8.01","item_title":"Other Events.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Iovance issued a press release on September 29, 2026 updating its full year 2026 revenue guidance from $350–$370 million to $410–$420 million, representing a $55 million increase at the midpoint (~15% upward revision). The disclosure includes financial metrics (record Q2 2026 revenue of $99.3 million, ~60% annual growth), operational updates (authorized treatment center expansion to ~100 centers), and forward-looking commentary on profitability. This is a material update to financial guidance that would affect a reasonable investor's assessment of the company's commercial performance and outlook.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-29T11:06:58.177352+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":39683,"accession_number":"0001104659-26-111583","item_number":"8.01","item_title":"Other Events.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Iovance issued a press release on September 29, 2026 updating its full year 2026 revenue guidance from $350–$370 million to $410–$420 million, representing a $55 million increase at the midpoint (~15% upward revision). The disclosure includes financial metrics (record Q2 2026 revenue of $99.3 million, ~60% annual growth), operational updates (authorized treatment center expansion to ~100 centers), and forward-looking commentary on profitability. This is a material update to financial guidance that would affect a reasonable investor's assessment of the company's commercial performance and outlook.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-29T11:06:58.177352+00:00","company_name":"IOVANCE BIOTHERAPEUTICS, INC.","ticker":"IOVA","filing_date":"2026-09-29"}]}